Abstract: Angioedema induced by renin-angiotensin-aldosterone system(RAAS) inhibitors is the result of increased production or decreased degradation of bradykinin. Dipeptidyl peptidase IV inhibitors are a class of oral diabetic agents that affect bradykinin and substance P degradation, therefore can lead to angioedema. Neprilysin inhibitors are a new type of medications that has the potential to improve the outcome of cardiovascular disease and can further increase the risk of medication-induced angioedema especially when combined with RAAS inhibitors. This review summarizes updated information of epidemiology, mechanism, symptoms and treatment of angioedema induced by these medications, in order to provide reference for the drug use.